Want to see TEM full AI Analyst Report?
Top Page
Tempus AI, Inc. Class A
(NASDAQ:TEM)
Select Model
Select Model
Rating:51Neutral
Price Target:
$45.00
▲(5.41% Upside)
Action:Reiterated
Date:07/31/26
TEM’s score is primarily held back by weak financial performance (ongoing losses, negative free cash flow, and high leverage) and bearish technicals (price below major moving averages with high volatility). Offsetting this, the latest earnings call was notably positive with raised 2026 revenue guidance and an improving adjusted EBITDA trajectory supported by strong growth and expanding biopharma contracts.
Positive Factors
Sustained high revenue growth and upgraded guidance
Consistent ~30%+ top-line growth and an upwardly revised full-year guide signal durable demand across diagnostics and data products. Multi-quarter bookings and TCV visibility give revenue predictability, supporting scale economics and a multi-year growth runway independent of short-term market moves.
Negative Factors
High leverage constraining flexibility
Debt materially exceeding equity (~3x) limits financial flexibility, increases interest and covenant risk, and narrows options for opportunistic investment. High leverage raises vulnerability to revenue or margin shocks and can constrain strategic choices during the multi-quarter build toward sustained profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained high revenue growth and upgraded guidance
Consistent ~30%+ top-line growth and an upwardly revised full-year guide signal durable demand across diagnostics and data products. Multi-quarter bookings and TCV visibility give revenue predictability, supporting scale economics and a multi-year growth runway independent of short-term market moves.
Read all positive factors
Tempus AI, Inc. Class A Key Performance Indicators (KPIs)
Any
Net Revenue by Segment
Breaks down the company’s revenue across its business lines (for example clinical sequencing and analytics, pharma partnerships, software/subscriptions, and research services). Reveals which segments drive growth, which are higher-margin or recurring, and whether revenue depends on a few large contracts or one-time projects — key for judging sustainability, profit potential, and exposure to reimbursement or partner risks.
Breaks down the company’s revenue across its business lines (for example clinical sequencing and analytics, pharma partnerships, software/subscriptions, and research services). Reveals which segments drive growth, which are higher-margin or recurring, and whether revenue depends on a few large contracts or one-time projects — key for judging sustainability, profit potential, and exposure to reimbursement or partner risks.
Data provided by:
The Fly
The FlyTempus AI, Inc. Class A (TEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.91B
Dividend YieldN/A
Average Volume (3M)5.68M
Price to Earnings (P/E)―
Beta (1Y)3.16
Revenue Growth50.43%
EPS Growth-21.05%
CountryUS
Employees3,800
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-1.43
Shares Outstanding175,200,070
10 Day Avg. Volume4,879,393
30 Day Avg. Volume5,678,843
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-41.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$62.15Price Target Upside45.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$1.60B
Tempus AI, Inc. Class A Business Overview & Revenue Model
Company Description
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analy...
How the Company Makes Money
Tempus AI primarily makes money through two core revenue streams: (1) clinical services and (2) data and services for life-sciences. In clinical services, Tempus generates revenue by providing diagnostic and profiling offerings (commonly including...
Tempus AI, Inc. Class A Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed strong topline momentum and durable demand in both diagnostics and data/applications: revenue growth (~36% YoY), robust Data & Insights growth (40.5% YoY; Insights >44%), expansion of large pharma collaborations (Merck, Gilead), rising bookings/TCV and an upgraded full-year revenue guide to $1.59B–$1.60B with adjusted EBITDA targeted at ~$65M. Key risks and near-term headwinds include Q1 cash-flow timing effects, slower hereditary volumes early in the year, MRD reimbursement and scaling constraints, and some regulatory timing uncertainty. Overall the positives (strong growth, expanding high-value contracts, improving EBITDA trajectory and sizable data assets) outweigh the transitory operational and reimbursement challenges.Positive Updates
Strong Overall Revenue Growth and Upgraded Guidance
Total revenue of $348.1M, up a little over 36% year-over-year. Company raised full-year revenue guidance to $1.59B–$1.60B and expects adjusted EBITDA of about $65M for FY2026.
Negative Updates
Q1 Cash Flow and Free Cash Variability
Cash flow from operations was down (management referenced roughly a $70M decline in operating cash flow for the quarter) and free cash approximated the small EBITDA loss in Q1. Company called out timing-driven issues (payables, bonuses, contract payment timing) and expects improvement in Q2.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Overall Revenue Growth and Upgraded Guidance
Total revenue of $348.1M, up a little over 36% year-over-year. Company raised full-year revenue guidance to $1.59B–$1.60B and expects adjusted EBITDA of about $65M for FY2026.
Read all positive updates
Company Guidance
Management raised 2026 revenue guidance to $1.59–$1.60 billion with adjusted EBITDA of about $65 million; that follows Q1 revenue of $348.1 million (up ~36% YoY), diagnostic revenue of $261.1 million (≈35% YoY) with oncology unit growth of ~28%, and data & applications revenue of $87 million (40.5% YoY) with Insights growth >44% and three straight quarters of bookings north of $100 million. They noted about $350 million of TCV tied to 2026 (and that TCV increased in Q1), added large deals with Merck and expanded Gilead, and said the connected database now exceeds 500 petabytes. Q1 adjusted EBITDA was roughly a $3 million loss (about a $13 million YoY improvement), free cash approximates EBITDA with Q1 seasonality expected to normalize in Q2, current ASPs are about $17.20–$17.40 with an illustrative ~$500 incremental ASP lift over 1–2 years (slides also showed a possible 30% ASP upside), MRD volume was up ~500% to ~6.5k tests, and management reiterated a target roughly in line with ~25% top‑line growth over the next three years.Tempus AI, Inc. Class A Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
34
Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.43B | 1.27B | 693.40M | 531.82M | 320.67M | 257.85M |
| Gross Profit | 916.19M | 797.90M | 381.11M | 286.18M | 130.19M | 83.64M |
| EBITDA | -90.90M | -118.51M | -610.42M | -133.33M | -236.85M | -219.52M |
| Net Income | -254.43M | -245.03M | -705.81M | -214.12M | -289.81M | -259.19M |
Balance Sheet | ||||||
| Total Assets | 2.37B | 2.27B | 926.12M | 564.05M | 631.36M | 531.35M |
| Cash, Cash Equivalents and Short-Term Investments | 815.99M | 755.00M | 448.26M | 197.57M | 302.94M | 277.69M |
| Total Debt | 1.44B | 1.33B | 468.09M | 488.14M | 433.03M | 238.95M |
| Total Liabilities | 1.92B | 1.78B | 869.78M | 1.95B | 1.76B | 1.34B |
| Stockholders Equity | 444.93M | 491.33M | 56.34M | -1.38B | -1.13B | -807.49M |
Cash Flow | ||||||
| Free Cash Flow | -272.97M | -245.35M | -211.17M | -248.95M | -186.58M | -223.75M |
| Operating Cash Flow | -237.43M | -218.09M | -189.04M | -214.34M | -168.20M | -211.98M |
| Investing Cash Flow | -34.19M | -398.36M | -130.39M | -40.31M | -57.94M | -21.72M |
| Financing Cash Flow | 687.93M | 884.12M | 494.33M | 117.55M | 251.39M | -2.04M |
Tempus AI, Inc. Class A Risk Analysis
Tempus AI, Inc. Class A disclosed 99 risk factors in its most recent earnings report. Tempus AI, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tempus AI, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $3.76B | 20.11 | 19.36% | ― | 13.05% | -12.34% | |
67 Neutral | $1.04B | 52.39 | 3.31% | ― | -1.19% | -21.87% | |
63 Neutral | $1.61B | 41.37 | 3.13% | ― | 8.45% | 72.08% | |
60 Neutral | $21.74B | -46.42 | 211.46% | ― | 42.74% | -4.60% | |
52 Neutral | $1.22B | -6.78 | -13.08% | ― | -2.08% | 16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $7.91B | -30.68 | -54.70% | ― | 50.43% | -21.05% |
* Healthcare Sector Average
TEM
Tempus AI, Inc. Class A
47.05
-8.48
-15.27%
OMCL
Omnicell
37.15
6.06
19.49%
TDOC
Teladoc
6.71
-0.28
-4.01%
GH
Guardant Health
159.79
115.20
258.35%
GDRX
GoodRx Holdings
3.34
-1.00
-23.04%
DOCS
Doximity
21.89
-36.24
-62.34%
Tempus AI, Inc. Class A Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Tempus AI Posts Strong Q2 Results, Raises 2026 Outlook
Positive
Jul 30, 2026
Tempus reported strong second-quarter 2026 results on July 30, 2026, with revenue rising 22% year over year to $382.5 million and gross profit up 26% to $246.5 million, driven by 31% oncology diagnostics volume growth and a 36% increase in data li...
Business Operations and StrategyM&A Transactions
Tempus AI Announces Merger Agreement to Acquire Personalis
Positive
Jul 20, 2026
On July 20, 2026, Tempus AI, Inc. signed a definitive merger agreement to acquire genomics company Personalis, Inc. through a two-step merger structure that will leave Toucan Development, LLC, a Tempus subsidiary, as the surviving entity. The boar...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Tempus AI to Acquire Personalis, Expanding Precision Oncology
Positive
Jul 20, 2026
Tempus AI, Inc. (NASDAQ: TEM) is a technology company focused on advancing precision medicine and patient care through artificial intelligence in healthcare. Leveraging one of the world’s largest libraries of multimodal clinical and molecula...
Executive/Board ChangesShareholder Meetings
Tempus AI Stockholders Confirm Board, Auditor and Say-on-Pay
Neutral
May 22, 2026
On May 21, 2026, Tempus AI, Inc. held its 2026 Annual Meeting of Stockholders, at which holders of both Class A and Class B common stock, voting together as a single class, elected nine directors to serve until the 2027 annual meeting or until ear...
Business Operations and StrategyPrivate Placements and Financing
Tempus AI Completes Convertible Notes Offering, Retires Secured Debt
Positive
May 13, 2026
On May 7, 2026, Tempus AI announced a private offering of $350 million in Convertible Senior Notes due 2032, with an option for an additional $52.5 million, aimed at optimizing its capital structure and reducing interest expense. The notes, which ...
Business Operations and StrategyFinancial Disclosures
Tempus AI Lifts 2026 Outlook on Robust Q1 Growth
Positive
May 5, 2026
Tempus AI reported on May 5, 2026 that first-quarter 2026 revenue rose 36.1% year-over-year to $348.1 million, driven by strong growth in diagnostics and data and applications, while gross profit climbed 43.1% and adjusted EBITDA loss narrowed to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.